Announcement of the Award-winning Enterprises in the Biomedical Industry for the 2025 Forbes China Industry Development Leaders

Frost & Sullivan

On March 22, 2025, the '2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor', co-hosted by Frost & Sullivan and Forbes China, was successfully held at the Shanghai Seagull Lijing Hotel.

At this grand event, a total of 21 outstanding experts and entrepreneurs in the medical field, 6 industry-leading enterprises, 2 influential institutions, an innovative brand, and an ESG benchmark were selected. These outstanding individuals and enterprises have demonstrated the vibrant vitality and development potential of China's medical industry with their exceptional innovation capabilities and relentless exploration spirit, painting a magnificent blueprint full of hope and dynamism for the future of the industry.

●Company IntroductionZhejiang Tongyuan Kang Medicine Co., Ltd. (TYK Medicines, Inc., stock code: 02410.HK) is a clinical-stage biopharmaceutical company focusing on cancer treatment, established in November 2017, headquartered in Huzhou, Zhejiang. The company is committed to developing small molecule targeted therapeutic drugs and possesses a small molecule drug design and screening platform, deuterated drug research and development technology platform, and macromolecular immunotherapy platform. Its core product, TY-9591, is a third-generation EGFR-TKI that is undergoing pivotal clinical trials. Tongyuan Kang Medicine successfully listed on the Hong Kong Stock Exchange on August 20, 2024, raising HK$579 million. The company plans to start operating its cGMP compliant production facility in Huzhou in the first quarter of 2025, with a designed annual production capacity of about 150 million tablets or capsules. In the future, the company will promote the commercialization of its core products through internal efforts and external cooperation, as well as expand the global market.

●Company IntroductionInner Mongolia OTCHIMON Pharmaceutical Co., Ltd. is a national high-tech enterprise, with more than ten subsidiaries including Ulanhot Zhongmeng Pharmaceutical Co., Ltd., Hohhot Jinshan Mongolian Medicine Factory, Inner Mongolia OTCHIMON Pharmaceutical Co., Ltd., Beijing Rangfeng Pharmaceutical Co., Ltd., and Xing'an League OTCHIMON Agricultural Resources Development Co., Ltd. It has formed a new development system for the entire Mongolian medicine industry chain, integrating Mongolian medicinal material planting, research and development, production, sales, and modern pharmaceutical logistics. Over the years, with the strong support of Party committees and governments at all levels, the company has made significant progress. It is now one of the Mongolian medicine production enterprises with the largest scale of infrastructure construction, the largest number of exclusive intellectual property Mongolian medicines, the most Mongolian medicine trade names, the widest sales network coverage, the largest market scale, the largest number of Mongolian medicines included in the national medical insurance catalog, and the earliest establishment of factories.

●Company IntroductionShaanxi Yungu Zhonghui Biopharmaceutical Co., Ltd. is an innovative enterprise focusing on the biomedical field, dedicated to researching, developing, producing, and selling high-quality biopharmaceutical products. The company focuses on the application of biotechnology in the pharmaceutical industry, promoting the development of the health industry through technological innovation and rigorous quality control, and providing advanced biomedical solutions to customers worldwide.

●Company IntroductionThe Shanghai Chuangqi Healthy Development Research Institute is established within the field of big health, aiming to promote in-depth exchanges and learning among industries, academia, government, investment, and media by connecting policy systems, technological development, and business models. It aims to create a platform that helps value innovation in the health industry and sustainable growth for leaders. The institute is guided by the Shanghai Health Commission. In 2019, Professor Cai Jiangnan, an expert in health economics and health policy, as the founder, with the support of government leaders, academic experts, industry leaders, and practitioners in the field of big health, joined forces with Professor Hu Shanlian from the School of Public Health at Fudan University, Professor Yu Wei from the School of Public Economics and Management at Shanghai University of Finance and Economics, and Professor Song Chengli from the School of Medical Devices and Food at ShanghaiTech University to promote the establishment of the institute. Adhering to the mission of 'Intelligent Leadership, Health Innovation, Value Creation', the institute conducts research consultations, learning exchanges, and conferences and forums around three levels: policy systems, industrial innovation, and technological development. By empowering leaders in the health industry, it aims to promote the renewal and upgrading of management capabilities in China's health industry; by building bridges between advanced domestic and international research achievements and market applications, it promotes value enhancement and innovation in the field of big health.

●Company IntroductionShanghai Zhongke New Life Biotechnology Co., Ltd. was established in 2004, originally as the external service platform of the Proteomics Research and Analysis Center at the Shanghai Institute of Life Sciences, Chinese Academy of Sciences. The company has formed an enterprise innovation research institute through technical cooperation with domestic and international research institutions and the innovative capabilities of its own R&D team. It has established four major technical platforms: a large-scale array multi-omics research technology platform, a preclinical CMC research and analysis platform for biopharmaceuticals, a platform for the registration and approval of biopharmaceuticals and medical devices, and an AI big data algorithm platform. The company has deployed three business segments: technology services, biomedicine, and consumer healthcare CRO services for the large health industry, constructing a business blueprint for life science and health that combines AI big data with mass spectrometry multi-omics technology applications.

●Company IntroductionSuzhou Xuanjing Biotechnology Co., Ltd. and Beijing Xuanjing Rui Medicine Technology Co., Ltd. were established in 2022. The company focuses on the research, development, and industrialization of innovative small nucleic acid drugs, aiming to be a pioneer and disruptor in the field of nucleic acid pharmaceuticals. The company has gathered a core team with over 10 years of industry experience, possessing rich expertise in various aspects such as nucleic acid biology, nucleic acid chemistry, hepatic and non-hepatic delivery, project management, pharmaceutical research, registration and application, clinical development, etc. The company has established a global independent intellectual property system (RIHOST) targeting key technical bottlenecks, intellectual property barriers, and future development directions in this field.^®RICMO^®LICOD^®The core technology platform has established multiple in vivo delivery technologies for non-liver tissues based on various exclusive strategies, making it a global leader in the research and development of non-liver delivery technologies and pipelines. The company has a profound understanding and differentiated considerations in target and indication selection. Liver-targeted products have already entered clinical research, and the development of a series of small nucleic acid drugs for non-liver tissues will be rapidly advanced to bring benefits to patients.

●Company IntroductionShuimu Future (Beijing) Technology Co., Ltd. is a new type of drug R&D platform company driven by A1+ cryo-electron microscopy. Based on core technologies such as structural biology, deep learning, and high-performance computing, the company promotes digital innovation in drug R&D in areas such as small molecules, antibody drugs, protein degradation, and gene therapy, helping global innovative pharmaceutical companies significantly improve their drug R&D efficiency and success rate.

● Company IntroductionHangzhou Deshi Biotechnology Co., Ltd. was established in 2016 and is a global leader in medical imaging AI and medical imaging equipment. It has seven subsidiaries and branches in countries and regions such as Singapore. The company is led by several national experts who oversee R&D, production, and sales teams. More than 50% of the R&D team has a master's degree or above and over 10 years of experience in the medical industry. The company has successively presided over and participated in several national and provincial-level scientific research projects, including special projects of the National Key Research and Development Program, and has created the world's largest medical imaging general large model with the largest parameter scale. It holds more than 60 core independent intellectual properties in multiple fields such as prenatal diagnosis, assisted reproduction, blood tumor diagnosis, and radiological health in China, the United States, Europe, and other places. The company has established a Zhejiang Provincial Enterprise R&D Center, training and exhibition center, a GMP production workshop with a capacity of 100,000 to 1 million units, mold processing and 3D printing workshops, etc. In 2019, it successfully released the world's first chromosome intelligent analysis system (AutoVision) based on AI technology.^®) and its high-precision scanning equipment (MetaSight^®In 2023, it won the certification of 'International First-Generation Equipment' from relevant government departments, and its market share of several core medical products has been steadily increasing.

●Company IntroductionJingzhi Future (Guangzhou) Intelligent Technology Co., Ltd. is a global leader in the field of breath testing, a national high-tech enterprise, one of the first projects signed for the Disruptive Technology Innovation Fund, and a recipient of the "National Disruptive Technology Innovation Key Special Project." Its products have been selected for the National "13th Five-Year Plan" Science and Technology Innovation Achievements Exhibition. Relying on its independently developed "Microelectromechanical (MEMS) + Microfluidic + Artificial Intelligence (AI)" integrated technology, the company has successfully launched the world's first chip-based breath molecular analysis micro gas chromatograph. It can accurately perform qualitative and quantitative analysis of volatile organic compounds (VOC) in human breath, with a detection sensitivity reaching the ppt level (one trillionth), breaking international monopolies and realizing the bedside, intelligent, and low-cost development of breath metabolomics testing equipment. Currently, this product has obtained Class II innovative medical device certification and has been implemented first in physical examination centers and community health scenarios. In the future, it can cover areas such as early cancer screening, rapid disease diagnosis, and home monitoring of chronic diseases, providing a new non-invasive, convenient, and inclusive disease diagnosis and management solution.

●Company IntroductionHefei Han Microbial Technology Co., Ltd. is the first domestic company to deeply explore the gut-brain axis, integrating natural microorganisms, metabolites, and synthetic biology. Han Microbial focuses on developing live bacterial drugs and small molecule drugs based on natural microbial metabolites as its core business. It has developed breakthrough therapies based on microorganisms for various immune and neurological diseases such as inflammatory bowel disease, IgA nephropathy, depression, and Parkinson's disease.

●Company IntroductionJiangsu Pulai Pharmaceutical Biotechnology Co., Ltd. was established in April 2009 and is a high-tech biopharmaceutical enterprise focusing on the research, development, and production of peptides and small molecule drugs. The company is located in the High-tech Development Zone of Jiangyin City, Jiangsu Province and is a national high-tech enterprise. It has wholly-owned R&D subsidiaries, Changchun Pulai Pharmaceutical Biotechnology Co., Ltd. and Nanjing TinoV Pharma Technology Co., Ltd., as well as subsidiaries Jiangsu Pulpe Pharma Technology Co., Ltd., Pulai Medical Holdings (Hong Kong) Co., Ltd., and Pulai Pharma (Australia) Co., Ltd.

The company's core development strategy is centered around innovative drug research, development, and production. It has established a variety of first-in-class peptide and small molecule new drug R&D pipelines led by national Class 1 anti-infection, anti-tumor, autoimmunity, and metabolic new drugs. The company currently holds dozens of patents, including PCT international invention patents, US and EU invention patents, Chinese invention patents, utility model and design patents, etc.

Since its establishment, the company has undertaken more than 40 scientific research projects, including major national science and technology projects such as the 12th Five-Year Plan and 13th Five-Year Plan 'Major New Drug Development', and the National 'Scholarly Exchange Students' Science and Technology Innovation and Entrepreneurship Project Selection Fund.

In the future, based on its existing antibacterial peptide series products, the company will continue to prioritize research and development alongside production and operation. It will explore the market with high-quality innovative products, striving to become a leader among international antibacterial peptide pharmaceutical enterprises!

●Company IntroductionPuxin Biotech, positioned as a global provider of integrated solutions for cell therapies, has its headquarters in Wuzhong District, Suzhou City, on the beautiful shores of Taihu Lake. It owns a Suzhou headquarters (10,000㎡ GMP factory building and R&D center) and an European headquarters in Liege, Wallonia region of Belgium, achieving global supply of cell preparations. Puxin Biotech focuses on the field of cell therapies and has established a dedicated HiPlasTM vector system and HiLenti for different types of cell therapies such as CAR-T, TCR-T, CAR-NK, TIL, and HSC.^®Suspension Serum-Free Virus Production Platform and HiCellx^®A cell process development platform with high transduction efficiency and a quality control platform. The platform has supported multiple partners in successfully incubating various drugs such as CAR-T, TCR-T, CAR-NK, and HSC, totaling more than 10 clinical approval documents from regulatory agencies including NMPA, EMA, and FDA, and has facilitated the conduct of multiple international multi-center clinical trial projects.

●Company IntroductionGuotou Innovation (Guotou Investment & Merchants) focuses on investment in advanced manufacturing industries, values technological innovation, outstanding entrepreneurs, and team values. It particularly invests in fields such as intelligent manufacturing, new energy intelligent vehicles, life sciences, information and communication technology, etc., aiming to promote the green, digital, and service-oriented development of manufacturing. The team has managed assets of nearly 100 billion RMB in total, with investors including financial institutions, social security funds, state-owned and private capital.

●Company IntroductionAnhui Zhongji Guoyi Medical Technology Co., Ltd. was established in January 2016 and is a pioneer and leader in the domestic medical supplies SPD smart supply chain. The company takes serving the high-quality development of Chinese hospitals as its mission and has pioneered the domestic third-party pure service model for SPD and the city-wide medical supplies smart management service center (CMS). Since its establishment, it has received capital injections from investors such as Hefei State-owned Assets Supervision and Administration Commission, Jifu Venture Capital, Xinli Capital, iFlytek, Qianhai Fund, Anhui Railway Fund, etc., and has introduced GF Securities, planning to go public as a whole in 2026.

●Company IntroductionJun Sai Biotech is committed to the development of innovative drugs and therapies for tumor infiltrating lymphocytes (TIL). Through recognition as a national high-tech enterprise and a specialized, refined, characteristic and innovative small and medium-sized enterprise in Shanghai, it has received the 'Shanghai May 1st Labor Medal' and developed into a leading enterprise in the field of TIL therapy in China. The company has independently established the internationally leading DeepTIL.^®Cell expansion and NovaGMP^®The company has developed a gene modification technology platform and a series of globally leading TIL cell drugs based on this platform. GC101, the world's first natural TIL therapy without chemoembolization or IL-2 injections, which is currently in pivotal Phase II clinical trials, and GC203, a non-viral vector gene modification TIL therapy in Phase I clinical trials, have demonstrated excellent clinical efficacy in the treatment of more than 10 different types of advanced solid tumors, leading in clinical progress domestically. The company's core technology has been deployed in nearly 50 Chinese invention patents and international PCT applications, and has received funding for 9 special projects from national-level bodies, Shanghai Science and Technology Commission, Development and Reform Commission, etc.

Wang Chenhui, Partner-in-Chief and President of Frost & Sullivan Greater China, and Guo Junyi, General Manager of Business Operations at Forbes China Group, jointly presented awards to representatives of the 2025 Forbes China Industry Development Pioneer Companies. Recipients include Li Zhan, Chairman of Anhui Zesheng Technology Co., Ltd., Liang Wenqing, Chairman and CEO of Changfeng Pharmaceutical Co., Ltd., Qu Chao, Founder and Vice Chairman of Pelt Medical Technology Co., Ltd., Li Zhi Le, Director, Chief Financial Officer, Board Secretary, and President of Pelt America of Shanghai Mengke Pharmaceutical Co., Ltd., Jiao Peng, Chairman and CEO of Bibo Biotech, and Guo Zhenyu, Chairman and CEO of Yunnan Baitai Biotechnology Group Co., Ltd.

●Company IntroductionAnhui Zesheng Technology Co., Ltd., as a national key “little giant” enterprise and high-tech enterprise focusing on specialized, refined, characteristic and innovative products, has achieved an all-round layout of its own brand portfolio “Annaiji”, “Sain Biomedical”, “3AMaterials”, “3ABio”, “3ASenrise”, covering the entire chemical industry chain and deeply involved in the fields of chemical reagents and pharmaceutical intermediates. The company focuses on industries such as medicine, semiconductors, and new energy, providing high-purity chemical raw materials and advanced material solutions, with products covering organic, inorganic, and equipment consumables. With outstanding independent innovation capabilities and strict quality control, it has built a global sales network and cooperated closely with leading enterprises in the industry. The company continues to increase investment in research and development, holds multiple core patents, and is committed to becoming a global leading supplier in niche fields.

●Company IntroductionChangfeng Pharmaceutical is a global emerging leader in inhalation delivery technology, focusing on the treatment of respiratory diseases. The company's mission is to develop innovative therapies to help patients breathe better. As one of the few companies worldwide that master the main inhalation formulations (the gold standard for treating respiratory diseases), the company has developed a rich portfolio of products. At the same time, the company actively explores innovative inhalation formulation dosage forms and extends its treatment areas to new disease areas, developing potential first-in-class or China-first-in-class treatments that comprehensively cover patients, medical specialties, and treatment areas. The company has obtained six product approvals from the National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and has achieved commercial success, demonstrating its strong capabilities in clinical development, production, regulatory affairs, and commercialization. Standing at the forefront of global innovation, the company is conducting global development of more than 20 candidate products in major markets such as China, the United States, Europe, emerging markets in Southeast Asia and South America, and more.

●Company IntroductionPanther Healthcare is a brand under Beijing Panther Medical Technology Co., Ltd. Panther Healthcare is a rapidly growing professional company rooted in China, focusing on the research, development, production, and sales of surgical instruments. The company was established in 2002 with its headquarters located in Beijing, covering more than 70 countries or regions across mainland China and overseas. In 2010, Panther Healthcare received investment from SoftBank China Venture Capital and became a foreign-invested enterprise. In May 2011, it was rated as a national high-tech enterprise. In January 2014, the company was ranked 90th among the most potential enterprises in China by Forbes magazine of the United States. After several years of rapid development, the company has become a leading brand among local stapler brands.

●Company IntroductionMengke Pharmaceutical is an innovative biopharmaceutical company centered on the treatment of infectious diseases, with global independent intellectual property rights and international competitiveness. It is committed to discovering, developing, and commercializing innovative drugs for unmet clinical needs. Since its establishment, the company has always adhered to the philosophy of "seeking good efficacy with good drugs," focusing on the increasingly serious bacterial resistance problem globally. With solving clinical challenges and differentiated innovation as its core competitiveness, the company aims to become a respected leader in innovative drug development, providing patients with better differentiated treatment products. The company has established R&D centers in China and the United States and has an international core R&D team. The company's R&D team has many years of experience in international innovative drug research and management, having led or participated in the development of several marketed anti-infective new drugs. The company insists on independent research and development, delves into specialized niche areas, and has established an integrated antibacterial new drug R&D system within the company, covering the entire new drug development process including early design and screening of innovative drugs, preclinical evaluation, global clinical development, registration application, and production management. The company adopts the operational model of simultaneous new drug development in China and the United States with international experience and standards.

●Company IntroductionBibo Biotech is one of the few CDMOs in the world capable of providing large-scale commercial production for biopharmaceutical companies. It has two R&D centers in Boston and Shanghai, as well as three GMP factories globally. The company has built multiple core technology platforms, including microbial fermentation, mammalian cell culture, XDC, and GMP production facility engineering customization services, providing customers with one-stop services covering the entire lifecycle of biopharmaceutical CMC.

Relying on PanFlex^®- Engineering technology. Bibo Biotech has built the world's first ultra-large-scale stainless steel mammalian cell production platform with a working volume of 30,000 liters per tank, and has achieved GMP production of biopharmaceutical products, filling a core technology gap in China's biopharmaceutical industry. It can provide the industry with a full range of production capacity solutions from 500 liters to 30,000 liters, helping customers gain comprehensive advantages in cost, product quality, and supply assurance.

The core team members of Bibo Biotech have experience leading over 130 projects, including 21 listed product projects, providing high-quality and efficient R&D and production services for numerous domestic and international partners. Driven by technology and demand, biopharmaceuticals are entering a fourth wave of biopharmaceutical manufacturing characterized by a 30,000-liter stainless steel bioreactor technology as the core, a total production capacity of one million liters as the foundation, and large-scale intensive production. As a leader in the fourth wave of biopharmaceutical manufacturing, Bibo Biotech independently designed the world's first 30,000-liter production platform and achieved an engineering and technological miracle of "Right on the First Time" and "Success on the First time" during the process of GMP production for biopharmaceutical products!

●Company IntroductionYunnan Betaine Biotechnology Group Co., Ltd. was established in 2010 and is a large health industry group integrating R&D, production, and marketing, positioned for the skin health internet+. The company went public on the ChiNext of the Shenzhen Stock Exchange on March 25, 2021, with the stock code 300957, becoming the first stock of efficacy skincare products in China.

●企业介绍：华熙生物（688363.SH）成立于2000年，是一家合成生物科技创新驱动的生物科技公司，生物材料全产业链平台公司。公司致力于“提高生命质量、延长生命长度”。公司的使命是“让每个生命都是鲜活的”，希望为人类持续带来健康美丽、快乐的生命体验。在全球生物科技产业迅猛发展的大背景下，华熙生物一直基于自身产业优势不断推动生命科学的进步。公司从生物学基础研究出发，聚焦糖生物学和细胞生物学这两大基础学科，依靠合成生物领域的产业转化优势，为生命健康提供科学解决方案，并从生物材料的上游研发开始，从原料生产贯通到品牌建设，探索了一条生物材料全链路转化的路径。

沙利文全球主管合伙人兼董事局执行董事祖亚儒（Aroop Zutshi）、福布斯中国集团商务运营总经理郭隽祎共同为2025福布斯中国行业发展领军企业依科赛生物科技股份有限公司、睿健医药iRegene、汉邦科技、深信生物（Innorna）颁奖。

●企业介绍：依科赛生物创立于2013年，以“加快生命科技应用，造福百姓健康”为使命，是国内生物制造上游领域关键原材料领军企业，是全球第五、国内最大胎牛血清生产商之一，国内首选GMP级别细胞基因治疗无血清培养基品牌，也是抗体培养基定制化和生物药质量检测试剂盒的领导企业，为生命科学研究和生物药产业赋能。公司是国家高新技术企业，国家级专精特新小巨人企业，中国首家国际血清行业协会（ISIA）会员单位，江苏省生物制药、细胞治疗等领域用CD无血清培养基工程研究中心、苏州质量奖企业。

公司依托国际化和专业化的研发技术团队、质量和生产团队以及商业化团队，持续创新，追求卓越，在不断优化产品性能的同时，确保可靠的质量和稳定的供应，其产品为国内外科研、生物药产业领域诸多头部客户广泛使用，全面赋能生物医药产业的快速健康发展，致力于成为全球生物制药和生命科学研究细胞培养工具的领导企业。

公司目前已服务超过10,000家客户遍布高校、研究所、医院、生物制药、基因测序等领域，在中国主要城市设有管理和营销中心，并在美国、澳大利亚和乌拉圭设有分公司。

●企业介绍：武汉睿健医药科技有限公司作为一家致力于成为全球领先的通用型化学诱导细胞治疗药物企业，是全球较早将“AI＋化学诱导”应用于细胞特定功能改造的Biotech公司。与基因治疗，及基因编辑疗法相比，该平台具有更为高效、安全、低成本且更适合大规模工业生产的优势。基于化学诱导这一独特平台，睿健医药建立了丰富的通用型细胞治疗产品管线，为以帕金森病为代表的神经退行性疾病、失明等“无法治愈”疾病开发通用型细胞治疗产品，带来治愈可能。

公司首款基于“化学诱导”平台研发的产品“人源多巴胺能前体细胞注射液NouvNeu001”已于2023年8月获得NMPA批准正式进入临床阶段，成为全球首个进入临床阶段的化学诱导iPSC衍生治疗产品，2024年6月也获得美国FDA开展海外临床，睿健也因此实现了全球首个人诱导多能干细胞（iPSC）衍生帕金森管线中美两地IND“双报双批”，更具有突破意义的是，睿健医药“化学诱导平台”在2024年3成为全球首个获得美国FDA特殊豁免资格的研发体系。面向早发型帕金森的第二款产品NouvNeu003也于2023年12月获得NMPA批准正式进入临床I期。目前，睿健的NouvNeu001和NouvNeu003均已完成Ⅰ期临床试验全部受试者入组给药，目前安全性、耐受性良好，并已顺利达成研究主要目的。此外，睿健医药的突破性眼科产品NouvSight001于2024年3月也被美国FDA授予孤儿药认定（ODD）。

到目前为止，睿健医药已成为国际iPSC领域获得监管机构认可最多，管线进展最快，治疗患者最多的领军企业，其独特的“化学诱导”细胞功能改造平台也在临床阶段进一步凸显出其独特优势，未来将会为患者带来更多突破性产品。

●企业介绍：汉邦科技是一家以色谱产品为核心的高新技术企业，主要为生物制药领域下游提供专业的分离纯化装备、耗材与技术服务。经过多年发展，公司形成了以小分子药物分离纯化装备、大分子药物分离纯化装备和实验室仪器设备为主的产品线，包括规格丰富、用途多样的各类分离纯化设备及配套设备、配件等，同时为客户提供制药工程下游分离纯化整体解决方案。

●企业介绍：深信生物于2019年创立，是一家递送技术平台型公司，主要从事核酸药物的递送技术开发，是国际范围内为数不多的掌握脂质纳米粒(LNP)底层技术的硬科技公司。深信生物拥有全球领先的具有自主知识产权的LNP递送技术，并在全球范围内进行了专利布局。

深信生物已与多家国内外生物医药公司达成合作，以共同开发或授权方式，使得更多的公司可以利用深信生物的LNP平台技术开发更多新型核酸药物。涉及的疾病领域包括罕见病、传染性疾病以及肿瘤等，部分管线已进入临床试验阶段。

福布斯中国集团商务运营总经理郭隽祎，沙利文合伙人兼中东、南亚、北非区总裁Robin Joffe共同为2025福布斯中国行业发展影响力机构代表颁奖。获奖机构：中国肝炎防治基金会、甫康（上海）健康科技有限责任公司、病痛挑战基金会。

●机构介绍：中国肝炎防治基金会是1996年6月由中国人民银行批准成立，1998年8月民政部注册登记的全国性公募基金会。2016年10月被民政部认定为慈善组织；2019年被民政部评为4A级社会组织。业务主管单位为国家卫生健康委员会，2022年7月由国家疾病预防控制局代管。业务范围包括：配合政府有关部门进行肝炎预防控制规划的实施，重点资助偏远、贫困地区开展肝炎防治工作；促进肝炎防治知识的传播与宣传动员；资助肝炎防治的科学研究，开展专业培训和技术咨询；组织开展肝炎患者互助互教交流活动；承接政府有关部门向社会组织购买服务的项目工作；推动国内、外友好往来，加强学术交流与合作。

中国肝炎防治基金会以“防治肝炎造福人类”为己任，以“积极募集资金与物资，开展公益活动，推动中国肝炎防治事业发展，提高全民族健康素质”为宗旨，落实“预防为主防治结合”的卫生健康方针，在民政部、国家卫生健康委员会、国家疾病预防控制局的领导下，积极募集资金与物资，在调查研究、建言献策、普及知识、推广干预模式、健康帮扶、人才培养、繁荣学术交流等方面充分发挥全国性公募基金会的作用。积极开展各类公益项目，直接惠及民众约1.1亿人次，是中国肝炎防治事业不可或缺的重要平台。

●机构介绍：甫康药业（Convalife Pharmaceuticals ）是一家立足中国、面向全球的处于临床阶段的新药研发企业，致力于在肿瘤、病毒和衰老疾病领域开发创新药物。甫康药业核心团队主要来自诺华、华海等国内外顶尖药企，与中科院上海药物所等国内外知名研究所持续合作。公司以中国及全球未满足的临床用药需求为导向，设计、研发具有“First-in-Class”或“Best-in-Class”潜力的原创新药，布局新一代双特异抗体生物药以及差异化小分子药物，为广大患者提供创新治疗方案。甫康药业肿瘤产品管线覆盖了乳腺癌、肺癌、胆管癌、前列腺癌、胰腺癌、胃癌等国内外急需创新治疗方案的实体肿瘤和血液肿瘤，包括已显示出“Best-in-Class”潜力的第二代PARP抑制剂CVL218，全球领先的PI3K β/δ双重高选择性抑制剂CVL237，还包括针对实体瘤的“First-in-Class”创新双特异性抗体等。甫康药业病毒产品管线包括针对多种传染性疾病进行药物研发，如新冠病毒、呼吸道合胞病毒、猴痘病毒、黄热病毒等。

●机构介绍：北京病痛挑战公益基金会（简称病痛挑战基金会，英文缩写ICF）是北京市第一家关注罕见病领域的公益基金会，致力于通过社群服务、行业支持、社会倡导，共同解决罕见病群体面临的迫切问题，为面临病痛挑战的人士，建立平等、受尊重的社会环境。本基金会缘起于“冰桶挑战”，于2016年2月29日国际罕见病日正式宣告成立。

ICF致力于支持罕见病病友的医疗康复、教育就业、社会融入等，培育积极行动的罕见病自组织，搭建多方参与的平台，打造公众链接感强的品牌项目，支持罕见病问题的制度保障，使每一个生命个体无论身患何种疾病、面临何种不便，都能获得尊重与善意，共同实现公平正义、多元共融的美好社会。

福布斯中国集团商务运营总经理郭隽祎，沙利文合伙人兼中东、南亚、北非区总裁Robin Joffe共同为2025福布斯中国行业发展行业发展ESG标杆平安健康医疗科技有限公司代表颁奖。

●公司介绍：平安健康医疗科技有限公司（股票简称：平安好医生，1833.HK），成立于2014年，是平安集团医疗养老生态圈的旗舰。公司于2018年5月4日在港交所挂牌上市，2020年7月获准纳入恒生科技指数。

凭借丰富的保险及金融客户端、企业端等医疗健康服务的支付方资源、广泛的服务供应商网络、完善的服务标准体系、强大的平安生态资源等核心竞争优势，平安健康深化落地管理式医疗战略，深耕“家庭医生”、“养老管家”两大核心枢纽建设，已成为专业、全面、高品质、一站式的医疗健康养老管理服务提供商。

福布斯中国集团商务运营总经理郭隽祎，沙利文合伙人兼中东、南亚、北非区总裁Robin Joffe共同为2025福布斯中国行业发展创新品牌科源制药代表颁奖。

●公司介绍：山东科源制药股份有限公司（301281.SZ）是国家高新技术企业、力诺集团健康产业核心成员企业、山东省化学合成药物骨干企业，致力于化学原料药产品研发、生产与销售以及国际高端CMO/CDMO业务的开发，与国际多家知名企业建立了战略合作伙伴关系。公司目前已经获得国内GMP证书、欧盟CEP证书，通过了美国FDA、加拿大、日本、韩国等国际官方认证。主要产品有盐酸二甲双胍、格列齐特、单硝酸异山梨酯、硝酸异山梨酯、盐酸罗哌卡因、乳糖酸克拉霉素、兰索拉唑、甲钴胺等，逐渐形成了降糖类、心血管类、麻醉剂类、抗肿瘤类、精神类等五大类药物并举的产品格局，为公司未来发展注入新的活力。公司拥有较为完善的生产、研发体系。生产厂区位于济南市商河县开发区，占地200余亩。公司研发拥有省级认定企业技术中心、市级博士后创新实践基地，拥有一支专业型、国际化的研发团队。 “致力于成为优秀的化药制造商”，科源制药始终秉承力诺集团“产业报国，追求卓越”的企业使命，在保持公司传统产品稳定增长的同时，大力发展CMO/CDMO业务，着力推进特色原料的产业布局，将科源制药打造成为国内一流、国际有影响力的公司，为人类健康事业做出更大贡献。